Construction of Quantitative Analysis Workflow for Determination of Serum Concentrations of Monoclonal Antibody Drugs Aiming to Promote Therapeutic Drug Monitoring in Clinical Practice-Reference-Cited by-同舟云学术

Construction of Quantitative Analysis Workflow for Determination of Serum Concentrations of Monoclonal Antibody Drugs Aiming to Promote Therapeutic Drug Monitoring in Clinical Practice

Published:2020-05-31 Issue:3 Volume:51 Page:161-166
ISSN:0388-1601
Container-title:Rinsho yakuri/Japanese Journal of Clinical Pharmacology and Therapeutics
language:en
Short-container-title:Jpn. J. Clin. Pharmacol. Ther.

Author:

NAITO Takafumi¹,SHIBATA Kaito¹,SHIDA Hiroaki¹,ABE Kazuki¹,KAWAKAMI Junichi¹

Affiliation:

1. Department of Hospital Pharmacy, Hamamatsu University School of Medicine, Hamamatsu, Japan

Publisher

Japanese Society of Clinical Pharmacology and Therapeutics

Subject

Pharmacology (medical),Pharmacology

Link

https://www.jstage.jst.go.jp/article/jscpt/51/3/51_161/_pdf

Reference22 articles.

1. 1) Fracasso PM, Burris H 3rd, Arquette MA, Govindan R, Gao F, Wright LP, et al. A phase 1 escalating single-dose and weekly fixed-dose study of cetuximab: pharmacokinetic and pharmacodynamic rationale for dosing. Clin Cancer Res. 2007; 13 (3) : 986-93. doi: 10.1158/1078-0432.CCR-06-1542.

2. 2) Yonemori K, Fujiwara Y, Minami H, Kitagawa K, Fujii H, Arai T, et al. Phase 1 trial of denosumab safety, pharmacokinetics, and pharmacodynamics in Japanese women with breast cancer-related bone metastases. Cancer Sci. 2008; 99 (6) : 1237-42. doi: 10.1111/j.1349-7006.2008.00803.x.

3. 3) Puszkiel A, Noé G, Boudou-Rouquette P, Cossec CL, Arrondeau J, Giraud JS, et al. Development and validation of an ELISA method for the quantification of nivolumab in plasma from non-small-cell lung cancer patients. J Pharm Biomed Anal. 2017; 139: 30-6. doi: 10.1016/j.jpba.2017.02.041.

4. 4) Grebenchtchikov N, Geurts-Moespot AJ, Heijmen L, van Laarhoven HW, van Herpen CM, Thijs AM, et al. Quantification of patient-specific assay interference in different formats of enzyme-linked immunoassays for therapeutic monoclonal antibodies. Ther Drug Monit. 2014; 36 (6) ; 765-70. doi: 10.1097/FTD.0000000000000090.

5. 5) Hoofnagle AN, Wener MH. The fundamental flaws of immunoassays and potential solutions using tandem mass spectrometry. J Immunol Methods. 2009; 347 (1-2) : 3-11. doi: 10.1016/j.jim.2009.06.003.